drugset / Trial / NCT06850571
Aflibercept and Bevacizumab for Diabetic Maculopathies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to to evaluate the clinical outcomes following treatment with bevacizumab versus aflibercept. These outcomes include: * Functional changes: The visual outcomes achieved by testing visual acuity * Anatomical changes: macular thickness and edema by optical coherence tomography (OCT).
Timeline
- Start
- 2025-02-20
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |
| Comparator | Bevacizumab | Monoclonal antibody | 1.25 mg | Intravitreal |